🔎 Trials Near Me

홈 › 신경교종 › 텍사스

텍사스의 신경교종 임상 시험

신경교종 관련 연구 26개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.

텍사스의 도시

공식 연구 텍스트(영어)

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • 외 8개
피험자 모집 중1/2상
12 Months – 21 Years · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05099003

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
  • Baylor College of Medicine, Houston
피험자 모집 중1/2상
25세 이하 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04094610

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

  • M D Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT03896568

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  • Texas Children's Hospital, Houston
피험자 모집 중2상
12 Months – 39 Years · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT06838676

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

  • M D Anderson Cancer Center, Houston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT04373720

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

  • M D Anderson Cancer Center, Houston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT04771806

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

  • The University of Texas M. D. Anderson Cancer Center, Houston
피험자 모집 중1상
36 Months · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT07076498

Targeted Pediatric High-Grade Glioma Therapy

  • Texas Children's Hospital, Houston
피험자 모집 중관찰 연구
12 Months – 39 Years · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT05839379

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

  • MD Anderson Cancer Center, Houston
피험자 모집 중1상
36 Months – 22 Years · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT03911388

Study of Olutasidenib and Temozolomide in HGG

  • Texas Children's Hospital, Houston
피험자 모집 중2상
12세 ~ 39세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
  • University of Texas Health Mays Cancer Center, San Antonio
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT05303519

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Texas Children's Hospital, Houston
피험자 모집 중2상
3세 ~ 39세 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT05096481

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

  • M D Anderson Cancer Center, Houston
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT01772771

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

  • University Of Texas Southwestern Medical Center, Dallas
피험자 모집 중1상
1세 ~ 25세 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT04485559

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  • Research Site, Houston
  • Research Site, San Antonio
피험자 모집 중1/2상
18세 ~ 130세 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT05417594

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

  • Excel Diagnostics & Nuclear Oncology Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 7. 업데이트됨 · NCT07733674

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

  • Texas Children's Hospital, Houston
피험자 모집 중1상
12 Months – 25 Years · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT04099797

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Baylor Scott & White Research Institute, Dallas
  • University of Texas MD Anderson Cancer Center, Houston
  • Baylor Scott & White Medical Center, Temple
피험자 모집 중2상
8세 이상 · 모든 성별 · 2026. 7. 27. 업데이트됨 · NCT05503797

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Texas Children's Hospital, Houston
피험자 모집 중초기 1상건강한 지원자 환영
1세 ~ 21세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT06333899

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

  • M D Anderson Cancer Center, Houston
피험자 모집 중초기 1상
18세 이상 · 모든 성별 · 2026. 6. 12. 업데이트됨 · NCT05804227

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Texas Children's Hospital, Houston
피험자 모집 중2상
12 Months – 39 Years · 모든 성별 · 2026. 5. 29. 업데이트됨 · NCT05843253

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  • MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 20. 업데이트됨 · NCT06326411

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT06810544

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Texas Children's Hospital, Houston
피험자 모집 중초기 1상
21세 이하 · 모든 성별 · 2026. 3. 18. 업데이트됨 · NCT04655404

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

  • The Cancer Therapy and Research Center at UTHSCSA, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 3. 30. 업데이트됨 · NCT05460507

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • UT Southwestern Medical Center, Dallas
  • The Cancer Therapy and Research Center at UTHSCSA, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 3. 26. 업데이트됨 · NCT01906385

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.